Olopatadine bests rupatadine for treating chronic idiopathic urticaria, finds study
Data from a recent study published in the Biomedical and Pharmacology Journal has demonstrated olopatadine to have superior efficiency and safety profile to rupatadine for the treatment of chronic idiopathic urticaria in adults patients.
Olopatadine is a well documented selective histamine H1 antagonist and mast cell stabilizer that works by attenuating inflammatory and allergic reactions. It is a structural analog of doxepin, which has a minimal anti-allergic activity.There are very few studies with a head-on comparison of Olopatadine to rupatadine.
To bridge this gap, Investigators enrolled a total of 60 patients with chronic idiopathic urticaria from the Department of Dermatology at Prathima Institute of Medical Sciences in Karimnagar, India. The population included both males and females that represented ages between 18-70 years. All patients experienced urticarial episodes 3 times a week for at least 4 consecutive weeks and exhibited no detectable causes.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.